Drug ID: 1d00000113
Drug Name: Apixaban
Generic Names: Eliquis
Category: Anticoagulants / Antithrombotics
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Recommended Dose: The recommended dose is 2.5 mg twice daily.
Recommended In: This medication is an anticoagulant, prescribed for reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation and for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery. It is a direct factor Xa inhibitor.
Directions For Use: It comes as a tablet to take by mouth, with or without food.
Storage: Store this medication as directed by your physician.
Dosage Forms: Tablet
Side Effects: Severe allergic reactions.
In Case of Overdose: There is no antidote to ELIQUIS. Overdose of Apixaban increases the risk of bleeding.
Avoid If: Caution should be exercised in patients with history of kidney or liver problems, bleeding problems, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.
Contraindicated in patients with abnormal bleeding and hypersensitivity. It should not be co-administered with unfractionated heparin (UFH), enoxaparin and dalteparin, fondaparinux, and oral anticoagulants.
Drug Interaction: Strong Dual Inhibitors Of CYP3A4 And P-gp
For patients receiving 5 mg twice daily, the dose of apixaban should be decreased to 2.5 mg twice daily when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
In patients already taking apixaban at a dose of 2.5 mg twice daily, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp.
Strong Dual Inducers Of CYP3A4 And P-gp
Avoid concomitant use of apixaban with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban.
Anticoagulants And Antiplatelet Agents
Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.